Chinese Medical Doctor Association
Pharmacoeconomics Chapter Annual Report 2012

TO:
Board of Directors
International Society for Pharmacoeconomics and Outcomes Research
505 Lawrence Square Blvd. South
Lawrenceville, NJ 08648 USA

PREPARED BY:
Dr. Wei Zhang, Vice Director
Chinese Medical Doctor Association Pharmacoeconomics Professional Committee (ISPOR
Chinese MDA-PE Chapter)
Chinese Medical Doctor Association
Room 519, No.3 Building
No.11 Dongzhimen Wai Xinzhong Road, Dongcheng District, Beijing, P. R. China
Email: pe@cmda.org.cn; wzhang@ceibs.edu

Background:
Chinese Medical Doctor Association Pharmacoeconomics Committee was approved by ISPOR in
January 2006.

The Chapter now has 510 members and the committee consists of well-known professionals on
Pharmacoeconomics, Clinical Medicine as well as Pharmacy. Current President is Dr. Shanlian Hu,
MD, MSc, Professor, School of Public Health, Fudan University, Shanghai, P. R. China, and
Director-General of Chinese Medical Doctor Association Pharmacoeconomics Professional
Committee.

The Chapter has always been devoted to disseminating the knowledge and skills of
Pharmacoeconomics and Outcomes Research. Much progress has been made in promoting
Pharmacoeconomics application in health system reform through embranchments of CDMA.

For more information, please visit http://www.ispor.org/regional_chapters/China/index.asp.
## Accomplishments Made in 2012

<table>
<thead>
<tr>
<th>Accomplishments</th>
<th>Major Aspects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mission</td>
<td>Promote the development and application of Pharmacoeconomics in China, and provide evidence and suggestion to pharmaceutical business and health departments by applying Pharmacoeconomics and Clinical Practice Economic Evaluation methodology to appraise the innovation of technology, organization and policy in the health sector.</td>
</tr>
<tr>
<td>Membership</td>
<td>Significant development has been made in membership recruitment from 341 in 2011 to 510 in 2012. Members recruited include professionals and young researchers from universities and research institutes, clinicians in general hospitals, community service centers, and hospitals in rural areas, as well as those working in pharmaceutical business.</td>
</tr>
<tr>
<td>Studies &amp; Projects</td>
<td>We devoted major efforts to advance the project <em>Innovation of Disease Management System in Rural China</em> which was initialed by the Ministry of Health and the World Bank this year. We also have started research on <em>Application of Clinical Practice Economic Evaluation in Health Insurance Management</em>. Additional studies of Pharmacoeconomic evaluation have been accomplished this year, such as chronic obstructive pulmonary disease, HBV.</td>
</tr>
<tr>
<td>Education &amp; Training</td>
<td>The chapter also made some significant steps forward in education and training in 2012. We held 6 useful courses in Beijing, Qinghai, Shaanxi, etc., such as the training course of <em>Application of Economic Evaluation in Essential Drug System and Health Insurance System</em> to provide opportunities for them to get continuing education credits that are accredited on a national scale and help capacity building. Those courses</td>
</tr>
</tbody>
</table>
also can train doctors and other relevant personnel in different clinical disciplines to disseminate the knowledge and skills of Pharmacoeconomics and Outcomes Research. About 400 people attended courses mainly including clinicians, pharmaceutical business workers and relative administrators.

The chapter has always been working hard to provide evidence and suggestion in essential drug policy, the third party payment model of health insurance, in order to help forward the establishment of national essential drug system, by conducting pharmaceutical evaluation research.

The Health XI Project which was initialed by the Ministry of Health and the World Bank in 2009, is designed to meet the challenges in health reform in rural China, such as establishing a health insurance system for rural residents, improving health service system, providing critical public health service, stimulating project cooperation and policy making. Thus, the project Innovation of Disease Management System in Rural China was initialed by CMDA-PE chapter to be an important part of the Health XI Project in 2011.

We contributed our major efforts in this project in 2012. Important data has been collected in Qinghai and analyzed by researchers of our project team. The disease management innovative solutions in rural China we proposed would contribute to the establishment of health insurance system for rural residents, improvement of health service system, and exploration of health system reform in rural areas of different development levels.

We have established a good cooperative relationship with the government, several organizations and companies in the health sector. In 2012, we have furthered our collaborative relationship with them by advancing the important part of the Health XI Project directed by MOH, continuing projects with China-Europe International Business School,
doing Pharmacoeconomics evaluation with Analysis Group in USA, China Pharmaceutical University, and Peking University Health Science Center as well.
<table>
<thead>
<tr>
<th><strong>The Plan of 2013</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Further development of membership</strong></td>
</tr>
<tr>
<td><strong>Developing international exchange program</strong></td>
</tr>
<tr>
<td><strong>Research prospect</strong></td>
</tr>
<tr>
<td><strong>About funding</strong></td>
</tr>
</tbody>
</table>